Home ›
Kidney Cancer Trials ›
NCT06255223
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
The objective of this single-center clinical study was to evaluate the disease control rate(DCR) and safety of multimodal radiotherapy in the treatment of patients with renal cell carcinoma (RCC) progressed after prior immunotherapy.
Trial Details
NCT ID NCT06255223
Phase PHASE2
Sponsor Jinling Hospital, China
Status RECRUITING
Cancer Type Kidney Cancer
Interventions High-dose Radiotherapy (HDRT) Low-dose Radiotherapy (LDRT) Anti-PD-1 monoclonal antibody
Locations (sample) Nanjing, Jiangsu, China|32.06167,118.77778
Key Eligibility Criteria
Renal cell carcinoma confirmed histologically or cytopathologically, including unresectable or recurrent metastatic renal cell carcinoma. Subject's previous treatment: Disease progression or intolerance following prior treatment with 1-2 systemic therapies (at least one regimen contai… Patients can tolerate sequential immunotherapy while receiving radiation therapy. At least two or more metastases at different sites are considered observable according to RECIST v1.1.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Kidney Cancer Trials on Trialify →